Abstract
Higher body mass index (BMI) has been found to predict greater antidepressant response to intravenous (IV) ketamine treatment. We evaluated the association between BMI and response to repeat-dose IV ketamine in patients with treatment-resistant depression (TRD). Adults (N=230) with TRD received four infusions of IV ketamine at a community-based clinic. Changes in symptoms of depression (ie, Quick Inventory for Depressive Symptomatology-Self-Report 16; QIDS-SR16), suicidal ideation (SI; ie, QIDS-SR16 SI item), anxiety (ie, Generalized Anxiety Disorder-7 Scale), anhedonic severity (ie, Snaith-Hamilton Pleasure Scale), and functioning (ie, Sheehan Disability Scale) following infusions were evaluated. Participants were stratified by BMI as normal (18.0-24.9kg/m2; n=72), overweight (25-29.9kg/m2; n=76), obese I (30-34.9kg/m2; n=47), or obese II (≥35.0kg/m2; n=35). Similar antidepressant effects with repeat-dose ketamine were reported between BMI groups (P=.261). In addition, categorical partial response (P=.149), response (P=.526), and remission (P=.232) rates were similar between the four BMI groups. The findings are limited by the observational, open-label design of this retrospective analysis. Pretreatment BMI did not predict response to IV ketamine, which was effective regardless of BMI.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have